المؤلفون: Su J; Oncology Department, Hangzhou Hospital of Traditional Chinese Medicine affiliated to Zhejiang Chinese Medical University, Hangzhou, China.; General Internal Medicine Department, Tongde Hospital of Zhejiang Province, Hangzhou, China., Ni C; Oncology Department, Hangzhou Hospital of Traditional Chinese Medicine affiliated to Zhejiang Chinese Medical University, Hangzhou, China., Wu Y; Endocrinology Department, Zhejiang Chinese Medical University, Hangzhou, China., Zhang J; Oncology Department, Hangzhou Hospital of Traditional Chinese Medicine affiliated to Zhejiang Chinese Medical University, Hangzhou, China., Cai Z; Oncology Department, Hangzhou Hospital of Traditional Chinese Medicine affiliated to Zhejiang Chinese Medical University, Hangzhou, China., Lu J; Oncology Department, Hangzhou Hospital of Traditional Chinese Medicine affiliated to Zhejiang Chinese Medical University, Hangzhou, China., Lin S; Department of Oncology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China., Wang J; Oncology Department, Hangzhou Hospital of Traditional Chinese Medicine affiliated to Zhejiang Chinese Medical University, Hangzhou, China.

المصدر: Expert review of anticancer therapy [Expert Rev Anticancer Ther] 2024 May; Vol. 24 (5), pp. 293-302. Date of Electronic Publication: 2024 Apr 01.

نوع المنشور: Systematic Review; Meta-Analysis; Journal Article; Comparative Study; Research Support, Non-U.S. Gov't; Review

بيانات الدورية: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101123358 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8328 (Electronic) Linking ISSN: 14737140 NLM ISO Abbreviation: Expert Rev Anticancer Ther Subsets: MEDLINE

مواضيع طبية MeSH: Pyridines*/adverse effects , Pyridines*/administration & dosage , Pyridines*/pharmacology , Anilides*/adverse effects , Anilides*/administration & dosage , Anilides*/pharmacology , Antineoplastic Agents*/adverse effects , Antineoplastic Agents*/administration & dosage , Antineoplastic Agents*/pharmacology , Neoplasms*/drug therapy , Neoplasms*/pathology , Randomized Controlled Trials as Topic* , Progression-Free Survival*, Humans ; Survival Rate ; Protein Kinase Inhibitors/adverse effects ; Protein Kinase Inhibitors/administration & dosage ; Protein Kinase Inhibitors/pharmacology ; Disease-Free Survival

المؤلفون: Stewart DJ; David J. Stewart, MD, University of Ottawa, Division of Medical Oncology, Ottawa, ON, Canada; Tim Ramsay, PhD, Ottawa Hospital Research Institute, Ottawa, ON, Canada; Vishal Navani, MBBS, University of Calgary, Calgary, AB, Canada; Geoffrey Liu, MD and Di Maria Jiang, MD, University of Toronto, Toronto, ON, Canada; and Gerald Batist, MDCM, McGill University, Montreal, QC, Canada., Ramsay T; David J. Stewart, MD, University of Ottawa, Division of Medical Oncology, Ottawa, ON, Canada; Tim Ramsay, PhD, Ottawa Hospital Research Institute, Ottawa, ON, Canada; Vishal Navani, MBBS, University of Calgary, Calgary, AB, Canada; Geoffrey Liu, MD and Di Maria Jiang, MD, University of Toronto, Toronto, ON, Canada; and Gerald Batist, MDCM, McGill University, Montreal, QC, Canada., Navani V; David J. Stewart, MD, University of Ottawa, Division of Medical Oncology, Ottawa, ON, Canada; Tim Ramsay, PhD, Ottawa Hospital Research Institute, Ottawa, ON, Canada; Vishal Navani, MBBS, University of Calgary, Calgary, AB, Canada; Geoffrey Liu, MD and Di Maria Jiang, MD, University of Toronto, Toronto, ON, Canada; and Gerald Batist, MDCM, McGill University, Montreal, QC, Canada., Liu G; David J. Stewart, MD, University of Ottawa, Division of Medical Oncology, Ottawa, ON, Canada; Tim Ramsay, PhD, Ottawa Hospital Research Institute, Ottawa, ON, Canada; Vishal Navani, MBBS, University of Calgary, Calgary, AB, Canada; Geoffrey Liu, MD and Di Maria Jiang, MD, University of Toronto, Toronto, ON, Canada; and Gerald Batist, MDCM, McGill University, Montreal, QC, Canada., Jiang DM; David J. Stewart, MD, University of Ottawa, Division of Medical Oncology, Ottawa, ON, Canada; Tim Ramsay, PhD, Ottawa Hospital Research Institute, Ottawa, ON, Canada; Vishal Navani, MBBS, University of Calgary, Calgary, AB, Canada; Geoffrey Liu, MD and Di Maria Jiang, MD, University of Toronto, Toronto, ON, Canada; and Gerald Batist, MDCM, McGill University, Montreal, QC, Canada., Batist G; David J. Stewart, MD, University of Ottawa, Division of Medical Oncology, Ottawa, ON, Canada; Tim Ramsay, PhD, Ottawa Hospital Research Institute, Ottawa, ON, Canada; Vishal Navani, MBBS, University of Calgary, Calgary, AB, Canada; Geoffrey Liu, MD and Di Maria Jiang, MD, University of Toronto, Toronto, ON, Canada; and Gerald Batist, MDCM, McGill University, Montreal, QC, Canada.

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Mar 10; Vol. 42 (8), pp. 973-974. Date of Electronic Publication: 2024 Jan 30.

نوع المنشور: Letter

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Neoplasms*/drug therapy , Antineoplastic Agents*/therapeutic use, Humans ; Progression-Free Survival ; Disease-Free Survival

المؤلفون: Zalimas A; Institute of Biosciences, Life Sciences Center, Vilnius University, Vilnius, Lithuania; algis.zalimas@gmail.com.; National Cancer Institute, Vilnius, Lithuania., Urbonas V; National Cancer Institute, Vilnius, Lithuania., Dabkeviciene D; National Cancer Institute, Vilnius, Lithuania., Purvaneckas J; Vilnius University, Faculty of Medicine, Vilnius, Lithuania., Ulys A; National Cancer Institute, Vilnius, Lithuania., Jarmalaite S; Institute of Biosciences, Life Sciences Center, Vilnius University, Vilnius, Lithuania.; National Cancer Institute, Vilnius, Lithuania.

المصدر: Anticancer research [Anticancer Res] 2024 Jan; Vol. 44 (1), pp. 213-219.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: International Institute of Anticancer Research Country of Publication: Greece NLM ID: 8102988 Publication Model: Print Cited Medium: Internet ISSN: 1791-7530 (Electronic) Linking ISSN: 02507005 NLM ISO Abbreviation: Anticancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Renal Cell*/pathology , Kidney Neoplasms*/pathology , Antineoplastic Agents*/therapeutic use, United States ; Humans ; Middle Aged ; Sunitinib/therapeutic use ; Retrospective Studies ; Lithuania ; National Cancer Institute (U.S.) ; Disease-Free Survival ; Prognosis

المؤلفون: Booth CM; Division of Cancer Care and Epidemiology, Queen's University Cancer Research Institute, Kingston, Canada.; Department of Oncology, Queen's University, Kingston, Canada.; Department of Public Health Sciences, Queen's University, Kingston, Canada., Eisenhauer EA; Department of Oncology, Queen's University, Kingston, Canada., Gyawali B; Division of Cancer Care and Epidemiology, Queen's University Cancer Research Institute, Kingston, Canada.; Department of Oncology, Queen's University, Kingston, Canada.; Department of Public Health Sciences, Queen's University, Kingston, Canada., Tannock IF; Division of Medical Oncology, Princess Margaret Cancer Centre and University of Toronto, Toronto, Canada.

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2023 Nov 10; Vol. 41 (32), pp. 4968-4972. Date of Electronic Publication: 2023 Sep 21.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents*/adverse effects, Humans ; Progression-Free Survival ; Disease-Free Survival

المؤلفون: Lee D; Center for Drug Evaluation and Research, Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, MD, USA. Electronic address: daniel.lee@fda.hhs.gov., Gittleman H; Center for Drug Evaluation and Research, Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, MD, USA., Weinstock C; Center for Drug Evaluation and Research, Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, MD, USA., Suzman D; Center for Drug Evaluation and Research, Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, MD, USA., Bloomquist E; Center for Drug Evaluation and Research, Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, MD, USA., Agrawal S; Center for Drug Evaluation and Research, Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, MD, USA., Brave M; Center for Drug Evaluation and Research, Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, MD, USA., Brewer J; Center for Drug Evaluation and Research, Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, MD, USA., Fallah J; Center for Drug Evaluation and Research, Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, MD, USA., Singh H; Center for Drug Evaluation and Research, Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, MD, USA., Tang S; Center for Drug Evaluation and Research, Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, MD, USA., Ibrahim A; Center for Drug Evaluation and Research, Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, MD, USA., Pazdur R; Center for Drug Evaluation and Research, Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, MD, USA., Beaver JA; Center for Drug Evaluation and Research, Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, MD, USA., Amiri-Kordestani L; Center for Drug Evaluation and Research, Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, MD, USA.

المصدر: European urology [Eur Urol] 2023 Oct; Vol. 84 (4), pp. 373-378. Date of Electronic Publication: 2023 Jun 02.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Science Country of Publication: Switzerland NLM ID: 7512719 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-7560 (Electronic) Linking ISSN: 03022838 NLM ISO Abbreviation: Eur Urol Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Renal Cell*/pathology , Antineoplastic Agents*/adverse effects , Kidney Neoplasms*/pathology, United States ; Humans ; Sunitinib/therapeutic use ; United States Food and Drug Administration ; Disease-Free Survival ; Protein Kinase Inhibitors/adverse effects ; Retrospective Studies

المؤلفون: Jaipuria J; Amity Centre for Cancer Epidemiology and Cancer Research, Amity Institute of Biotechnology, Amity University, Noida, Uttar Pradesh, India., Jain A; Uro-Oncology Division, Rajiv Gandhi Cancer Institute and Research Centre, Rohini, Sector - 5, New Delhi, India., Gupta S; Uro-Oncology Division, Rajiv Gandhi Cancer Institute and Research Centre, Rohini, Sector - 5, New Delhi, India., Sadasukhi N; Uro-Oncology Division, Rajiv Gandhi Cancer Institute and Research Centre, Rohini, Sector - 5, New Delhi, India., Kasaraneni P; Uro-Oncology Division, Rajiv Gandhi Cancer Institute and Research Centre, Rohini, Sector - 5, New Delhi, India., Singh A; Uro-Oncology Division, Rajiv Gandhi Cancer Institute and Research Centre, Rohini, Sector - 5, New Delhi, India., Gupta K; Catalyst Clinical Services Pvt. Ltd., New Delhi, India., Sharma G; Amity Centre for Cancer Epidemiology and Cancer Research, Amity Institute of Biotechnology, Amity University, Noida, Uttar Pradesh, India., Talwar V; Medical Oncology Division, Rajiv Gandhi Cancer Institute and Research Centre, Rohini, Sector - 5, New Delhi, India., Rawal SK; Uro-Oncology Division, Rajiv Gandhi Cancer Institute and Research Centre, Rohini, Sector - 5, New Delhi, India.

المصدر: Indian journal of cancer [Indian J Cancer] 2023 Oct 01; Vol. 60 (4), pp. 493-500. Date of Electronic Publication: 2024 Jan 09.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Medknow Publications Country of Publication: India NLM ID: 0112040 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1998-4774 (Electronic) Linking ISSN: 0019509X NLM ISO Abbreviation: Indian J Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Renal Cell*/pathology , Antineoplastic Agents*/adverse effects , Kidney Neoplasms*/pathology, Adult ; Humans ; Sunitinib/therapeutic use ; Indoles/adverse effects ; Pyrroles/adverse effects ; Treatment Outcome ; Disease-Free Survival ; Retrospective Studies

SCR Disease Name: Clear-cell metastatic renal cell carcinoma

المؤلفون: Hogan LE; Department of Pediatrics, Stony Brook Children's, Stony Brook, NY., Brown PA; Bristol Myers Squibb, Princeton, NJ., Ji L; Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA., Xu X; Children's Oncology Group, Monrovia, CA., Devidas M; Department of Global Pediatric Medicine, St Jude Children's Research Hospital, Memphis, TN., Bhatla T; Childrens Hospital of New Jersey at Newark Beth Israel, Newark, NJ., Borowitz MJ; Departments of Pathology and Oncology, Johns Hopkins University School of Medicine, Baltimore, MD., Raetz EA; Department of Pediatrics, NYU Langone Health, New York, NY., Carroll A; University of Alabama at Birmingham, Birmingham, AL., Heerema NA; Department of Pathology, The Ohio State University, Columbus, OH., Zugmaier G; Amgen Research (Munich), GmbH, Munich, Germany., Sharon E; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Cancer Therapy Evaluation Program, Bethesda, MD., Bernhardt MB; Section of Hematology/Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, TX., Terezakis SA; Department of Radiation Oncology, University of Minnesota, Minneapolis, MN., Gore L; University of Colorado School of Medicine and Center for Cancer and Blood Disorders, Children's Hospital Colorado, Aurora, CO., Whitlock JA; Hospital for Sick Children and University of Toronto, Toronto, Canada., Hunger SP; Department of Pediatrics and the Center for Childhood Cancer Research, Children's Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA., Loh ML; Ben Towne Center for Childhood Cancer Research, Seattle Children's Research Institute, Seattle, WA.; Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle, WA.

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2023 Sep 01; Vol. 41 (25), pp. 4118-4129. Date of Electronic Publication: 2023 May 31.

نوع المنشور: Randomized Controlled Trial; Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents*/adverse effects , Antibodies, Bispecific*/adverse effects, Humans ; Child ; Adolescent ; Young Adult ; Infant ; Child, Preschool ; Adult ; Disease-Free Survival ; Recurrence

المؤلفون: Corbaux P; EA UCBL/HCL 3738, Centre pour l'lnnovation en Cancérologie de Lyon (CICLY), Faculty of Medicine Lyon-Sud, Claude Bernard University Lyon 1, Lyon, France; Medical Oncology, Institut de Cancérologie et d'Hématologie Universitaire de Saint-Étienne (ICHUSE), Centre Hospitalier Universitaire de Saint-Etienne, France., You B; EA UCBL/HCL 3738, Centre pour l'lnnovation en Cancérologie de Lyon (CICLY), Faculty of Medicine Lyon-Sud, Claude Bernard University Lyon 1, Lyon, France; Medical Oncology, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), CITOHL, Centre Hospitalier Lyon-Sud, GINECO, GINEGEPS, Lyon, France. Electronic address: benoit.you@chu-lyon.fr., Glasspool RM; Beatson West of Scotland Cancer Centre, NHS Greater Glasgow and Clyde, Glasgow, UK., Yanaihara N; Department of Obstetrics and Gynecologye, The Jikei University School of Medicine, Tokyo, Japan., Tinker AV; Medical Oncology, BC Cancer - Vancouver, Vancouver, Canada., Lindemann K; Department of Gynaecological Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway., Ray-Coquard IL; Medical Oncology Department, Centre Léon Bérard, GINECO, Lyon, France., Mirza MR; Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; Clinical Trial Unit, Nordic Society of Gynaecological Oncology, Copenhagen, Denmark., Subtil F; Department of Biostatistics, Hospices Civils de Lyon, Laboratoire de Biométrie et Biologie Evolutive, Equipe Biostatistique Santé, CNRS UMR 5558, Claude Bernard University Lyon 1, Lyon, France., Colomban O; EA UCBL/HCL 3738, Centre pour l'lnnovation en Cancérologie de Lyon (CICLY), Faculty of Medicine Lyon-Sud, Claude Bernard University Lyon 1, Lyon, France., Péron J; Medical Oncology, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), CITOHL, Centre Hospitalier Lyon-Sud, GINECO, GINEGEPS, Lyon, France; Department of Biostatistics, Hospices Civils de Lyon, Laboratoire de Biométrie et Biologie Evolutive, Equipe Biostatistique Santé, CNRS UMR 5558, Claude Bernard University Lyon 1, Lyon, France., Karamouza E; Institut Gustave Roussy, Office of Biostatistics and Epidemiology, Université Paris-Saclay, Villejuif, France; Inserm, Université Paris-Saclay, CESP U1018, Oncostat, labelled Ligue Contre le Cancer, Villejuif, France., McNeish I; Department of Surgery and Cancer, Imperial College London, London, UK., Kelly C; Cancer Research UK Clinical Trial Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK., Kagimura T; Foundation for Biomedical Research and Innovation at Kobe, Translational Research Center for Medical Innovation, Kobe, Japan., Welch S; Department of Oncology, London Health Sciences Centre, London, Ontario, Canada., Lewsley LA; Cancer Research UK Clinical Trial Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK., Paoletti X; Institut Curie, St Cloud, France., Cook A; Medical Research Council Clinical Trials Unit, University College London, London, UK.

المصدر: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2023 Sep; Vol. 191, pp. 112966. Date of Electronic Publication: 2023 Jul 04.

نوع المنشور: Meta-Analysis; Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents*/therapeutic use , Ovarian Neoplasms*/drug therapy , Ovarian Neoplasms*/surgery, Humans ; Female ; Poly(ADP-ribose) Polymerase Inhibitors/therapeutic use ; CA-125 Antigen ; Disease-Free Survival

المؤلفون: Zhao W; Department of Respiratory Medicine, Strategic Support Force Medical Center.; Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chaoyang Hospital, Capital Medical University, Beijing, China., Zhu M; Department of Respiratory Medicine, Strategic Support Force Medical Center., Wang R; Department of Respiratory Medicine, Strategic Support Force Medical Center., Tong Z; Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.

المصدر: Anti-cancer drugs [Anticancer Drugs] 2023 Jun 01; Vol. 34 (5), pp. 686-689. Date of Electronic Publication: 2022 Oct 06.

نوع المنشور: Case Reports; Journal Article

بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: England NLM ID: 9100823 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1473-5741 (Electronic) Linking ISSN: 09594973 NLM ISO Abbreviation: Anticancer Drugs Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Non-Small-Cell Lung*/drug therapy , Lung Neoplasms*/drug therapy , Antineoplastic Agents*/therapeutic use , Adenocarcinoma of Lung*/drug therapy, Female ; Humans ; Child, Preschool ; Pemetrexed ; Disease-Free Survival ; Cisplatin ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use

المؤلفون: Tsutani Y; Division of Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine, Osaka-Sayama, Japan. Electronic address: yatsutani@msn.com., Goldman JW; David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA., Dacic S; Department of Pathology, Yale School of Medicine, New Haven, CT., Yatabe Y; Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan., Majem M; Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain., Huang X; Oncology Biometrics, AstraZeneca, Cambridge, United Kingdom., Chen A; Late Oncology Research & Development, AstraZeneca, New York, NY., van der Gronde T; Late Oncology Research & Development, AstraZeneca, New York, NY., He J; Thoracic Surgery Department, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

المصدر: Clinical lung cancer [Clin Lung Cancer] 2023 Jun; Vol. 24 (4), pp. 376-380. Date of Electronic Publication: 2023 Feb 08.

نوع المنشور: Clinical Trial Protocol; Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 100893225 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0690 (Electronic) Linking ISSN: 15257304 NLM ISO Abbreviation: Clin Lung Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents*/therapeutic use , Protein Kinase Inhibitors*/therapeutic use , Carcinoma, Non-Small-Cell Lung*/drug therapy , Lung Neoplasms*/drug therapy, Humans ; Clinical Trials, Phase III as Topic ; Double-Blind Method ; Placebos ; Randomized Controlled Trials as Topic ; Disease-Free Survival